

Contents

Preface *xiii*

Part I Continuous Biomanufacturing *1*

1	Strategies for Continuous Processing in Microbial Systems	3
	<i>Julian Kopp, Christoph Slouka, Frank Delvigne, and Christoph Herwig</i>	
1.1	Introduction	3
1.1.1	Microbial Hosts and Their Applications in Biotechnology	3
1.1.2	Regulatory Demands for Their Applied Cultivation Mode	5
1.2	Overview of Applied Cultivation Methods in Industrial Biotechnology	6
1.2.1	Batch and Fed-Batch Cultivations	7
1.2.1.1	Conventional Approaches and Their Technical Limitations	7
1.2.1.2	Feeding and Control Strategies Using <i>E. coli</i> as a Model Organism	8
1.2.2	Introduction into Microbial Continuous Biomanufacturing (CBM)	9
1.2.2.1	General Considerations	9
1.2.2.2	Mass Balancing and the Macroscopic Effects in Chemostat Cultures	11
1.2.3	Microbial CBM vs. Mammalian CBM	13
1.2.3.1	Differences in Upstream of Microbial CBM Compared with Cell Culture	13
1.2.3.2	Downstream in Microbial CBM	14
1.3	Monitoring and Control Strategies to Enable CBM with Microbials	16
1.3.1	Subpopulation Monitoring and Possible PAT Tools Applicable for Microbial CBM	16
1.3.2	Modeling and Control Strategies to Enable CBM with Microbials	19
1.4	Chances and Drawbacks in Continuous Biomanufacturing with <i>E. coli</i>	21
1.4.1	Optimization of Plant Usage Using CBM with <i>E. coli</i>	21
1.4.2	Reasons Why CBM with <i>E. coli</i> Is Not State of the Art (Yet)	23
1.4.2.1	Formation of Subpopulation Following Genotypic Diversification	23
1.4.2.2	Formation of Subpopulation Following Phenotypic Diversification	25

1.4.2.3	Is Genomic Integration of the Target Protein an Enabler for CBM with <i>E. coli</i> ? 26
1.4.3	Solutions to Overcome the Formation of Subpopulations and How to Realize CBM with <i>E. coli</i> in the Future 27
1.5	Conclusion and Outlook 29
	References 30
2	Control of Continuous Manufacturing Processes for Production of Monoclonal Antibodies 39
	<i>Anurag S. Rathore, Garima Thakur, Saxena Nikita, and Shantanu Banerjee</i>
2.1	Introduction 39
2.2	Control of Upstream Mammalian Bioreactor for Continuous Production of mAbs 40
2.3	Integration Between Upstream and Downstream in Continuous Production of mAbs 46
2.3.1	Continuous Clarification as a Bridge Between Continuous Upstream and Downstream 46
2.3.2	Considerations for Process Integration 48
2.4	Control of Continuous Downstream Unit Operations in mAb Manufacturing 49
2.4.1	Control of Continuous Dead-End Filtration 49
2.4.2	Control of Continuous Chromatography 50
2.4.3	Control of Continuous Viral Inactivation 53
2.4.4	Control of Continuous Precipitation 54
2.4.5	Control of Continuous Formulation 56
2.5	Integration Between Adjacent Unit Operations Using Surge Tanks 57
2.6	Emerging Approaches for High-Level Monitoring and Control of Continuous Bioprocesses 59
2.6.1	Artificial Intelligence (AI) and Machine Learning (ML) Control 60
2.6.2	Statistical Process Control 61
2.6.3	Process Digitalization 62
2.7	Conclusions 63
	References 63
3	Artificial Intelligence and the Control of Continuous Manufacturing 75
	<i>Steven S. Kuwahara</i>
3.1	Introduction 75
3.2	Continuous Monitoring and Validation 84
3.3	Choosing Other Control Charts 84
3.4	Information Awareness 85
3.5	Management and Personnel 86
	References 90

Part II Intensified Biomanufacturing 93**4 Bioprocess Intensification: Technologies and Goals 95***William G. Whitford*

- 4.1 Introduction 95
 - 4.2 Bioprocess Intensification 98
 - 4.2.1 Definition 98
 - 4.2.2 New Directions 100
 - 4.2.3 Sustainability Synergy 102
 - 4.3 Intensification Techniques 103
 - 4.3.1 Enterprise Resource Management 103
 - 4.3.2 Synthetic Biology and Genetic Engineering 104
 - 4.3.3 New Expression Systems 105
 - 4.3.4 Bioprocess Optimization 106
 - 4.3.5 Bioprocess Simplification 107
 - 4.3.6 Continuous Bioprocessing 108
 - 4.4 Materials 109
 - 4.4.1 Media Optimization 109
 - 4.4.2 Variability 110
 - 4.5 Digital Biomanufacturing 110
 - 4.5.1 Data 111
 - 4.5.2 Bioprocess Control 112
 - 4.5.3 Digital Twins 113
 - 4.5.4 Artificial Intelligence 114
 - 4.5.5 Cloud/Edge Computing 114
 - 4.6 Bioprocess Modeling 114
 - 4.7 Automation and Autonomation 115
 - 4.8 Bioprocess Monitoring 117
 - 4.9 Improved Process and Product Development 118
 - 4.9.1 Design of Experiments 118
 - 4.9.2 QbD and PAT 119
 - 4.9.3 High-Throughput Systems 119
 - 4.9.4 Methods 120
 - 4.9.5 Commercialized Systems 120
 - 4.10 Advanced Process Control 121
 - 4.11 Bioreactor Design 121
 - 4.12 Single-Use Systems 122
 - 4.13 Facilities 123
 - 4.14 Conclusion 126
- Abbreviations and Acronyms 126
- Acknowledgment 129
- References 129

5 Process Intensification Based on Disposable Solutions as First Step Toward Continuous Processing 137

Stefan R. Schmidt

- 5.1 Introduction 137
 - 5.1.1 Theory and Practice of Process Intensification 137
 - 5.1.2 Current Bioprocessing 140
 - 5.1.3 General Aspects of Disposables 140
- 5.2 Technical Solutions 141
 - 5.2.1 Process Development 141
 - 5.2.2 Upstream Processing Unit Operations 142
 - 5.2.2.1 High-Density, Large-Volume Cell Banking in Bags 143
 - 5.2.2.2 Seed Train Intensification 144
 - 5.2.2.3 Cell Retention and Harvest 145
 - 5.2.3 Downstream Processing Unit Operations 149
 - 5.2.3.1 Depth Filtration 149
 - 5.2.3.2 In-line Virus Inactivation 151
 - 5.2.3.3 In-line Buffer Blending and Dilution 152
 - 5.2.3.4 Chromatography 153
 - 5.2.3.5 Tangential Flow Filtration 159
 - 5.2.3.6 Drug Substance Freezing 161
- 5.3 Process Analytical Technology and Sensors 162
 - 5.3.1 Sensors for USP Applications 163
 - 5.3.2 Sensors for DSP Applications 164
- 5.4 Conclusions 165
 - 5.4.1 Transition from Traditional to Intensified Processes 165
 - 5.4.2 Impact on Cost 169
 - 5.4.3 Influence on Time 170
- References 171

6 Single-Use Continuous Manufacturing and Process Intensification for Production of Affordable Biological Drugs 179

Ashish K. Joshi and Sanjeev K. Gupta

- 6.1 Background 179
- 6.2 State of Upstream and Downstream Processes 180
 - 6.2.1 Sizing Upstream Process 181
 - 6.2.2 Sizing Downstream Process 182
 - 6.2.3 Continuous Process Retrofit into the Existing Facility 184
 - 6.2.3.1 Upstream Process 184
 - 6.2.3.2 Downstream Process 184
 - 6.2.4 Learning from Chemical Industry 185
- 6.3 Cell Line Development and Manufacturing Role 186
 - 6.3.1 Speeding Up Upstream and Downstream Development 188
 - 6.3.2 The State of Manufacturing 189
- 6.4 Process Integration and Intensification 190

6.4.1	Intensification of a Multiproduct Perfusion Platform	190
6.4.2	Upstream Process Intensification Using Perfusion Process	192
6.5	Process Intensification and Integration in Continuous Manufacturing	192
6.6	Single-Use Manufacturing to Maximize Efficiency	194
6.6.1	The Benefits of SUT in the New Era of Biomanufacturing	195
6.6.2	Managing an SUT Cost Profile	195
6.6.3	In-Line Conditioning (ILC)	196
6.6.4	Impact of Single-Use Strategy on Manufacturing Cost of Goods	197
6.6.5	Limitations of SUT	198
6.7	Process Economy	199
6.7.1	Biopharma Market Dynamics	200
6.7.2	Management of the Key Risks of a Budding Market	201
6.8	Future Perspective	202
	References	203

Part III Digital Biomanufacturing 209

7 Process Intensification and Industry 4.0: Mutually Enabling Trends 211

Marc Bisschops and Loe Cameron

7.1	Introduction	211
7.2	Enabling Technologies for Process Intensification	213
7.2.1	Process Intensification in Biomanufacturing	213
7.2.2	Process Intensification in Cell Culture	214
7.2.3	Process Intensification in Downstream Processing	214
7.2.4	Process Integration: Manufacturing Platforms	216
7.2.5	The Two Elephants in the (Clean) Room	217
7.3	Digital Opportunities in Process Development	220
7.4	Digital Opportunities in Manufacturing	222
7.5	Digital Opportunities in Quality Assurance	223
7.6	Considerations	224
7.6.1	Challenges	224
7.6.2	Gene Therapy	226
7.7	Conclusions	227
	References	227

8 Consistent Value Creation from Bioprocess Data with Customized Algorithms: Opportunities Beyond Multivariate Analysis 231

Harini Narayanan, Moritz von Stosch, Martin F. Luna, M.N. Cruz Bournazou, Alessandro Buttè, and Michael Sokolov

8.1	Motivation	231
8.2	Modeling of Process Dynamics	232

8.2.1	Hybrid Models	234
8.2.2	Conclusion	238
8.3	Predictive Models for Critical Quality Attributes	238
8.3.1	Historical Product Quality Prediction	238
8.3.2	Synergistic Prediction of Process and Product Quality	242
8.4	Extrapolation and Process Optimization	242
8.5	Bioprocess Monitoring Using Soft Sensors	247
8.5.1	Static Soft Sensor	248
8.5.2	Dynamic Soft Sensors	250
8.5.3	Concluding Remarks	251
8.6	Scale-Up and Scale-Down	251
8.6.1	Differences Between Lab and Manufacturing Scales	252
8.6.2	Scale-Up	253
8.6.3	Scale-Down	254
8.6.4	Conclusions	255
8.7	Digitalization as an Enabler for Continuous Manufacturing	255
	References	257
9	Digital Twins for Continuous Biologics Manufacturing	265
	<i>Axel Schmidt, Steffen Zobel-Roos, Heribert Helgers, Lara Lohmann, Florian Vetter, Christoph Jensch, Alex Juckers, and Jochen Strube</i>	
9.1	Introduction	265
9.2	Digital Twins in Continuous Biomanufacturing	269
9.2.1	USP Fed Batch and Perfusion	273
9.2.2	Capture, LLE, Cell Separation, and Clarification	273
9.2.2.1	Fluid Dynamics (Red)	277
9.2.2.2	Phase Equilibrium (Blue)	277
9.2.2.3	Kinetics (Green)	277
9.2.3	UF/DF, SPTFF for Concentration, and Buffer Exchange	278
9.2.4	Precipitation/Crystallization	282
9.2.5	Chromatography and Membrane Adsorption	282
9.2.5.1	General Rate Model Chromatography	282
9.2.5.2	SEC	284
9.2.5.3	Adsorption Mechanism	284
9.2.5.4	IEX-SMA	284
9.2.5.5	HIC-SMA	285
9.2.5.6	Modified Mixed-Mode SMA	285
9.2.5.7	Modified HIC-SMA Process Model Exemplification by mab Purification	287
9.2.5.8	Model Parameter Determination	289
9.2.5.9	Phase Equilibrium Isotherms	290
9.2.5.10	Mass Transfer Kinetics	292
9.2.6	Lyophilization	293
9.2.6.1	Thermal Conductivity of the Vial	293
9.2.6.2	Product Resistance	293

9.2.6.3	Product Temperature	295
9.2.6.4	Water Properties	295
9.3	Process Integration and Demonstration	295
9.3.1	USP Fed Batch and Perfusion	301
9.3.2	Capture, LLE, Cell Separation, and Clarification	306
9.3.3	UF/DF, SPTFF for Concentration, and Buffer Exchange	309
9.3.4	Precipitation/Crystallization	311
9.3.5	Chromatography and Membrane Adsorption	314
9.3.6	Lyophilization	314
9.3.7	Comparison Between Conceptual Process Design and Experimental Data	319
9.4	PAT in Continuous Biomanufacturing	320
9.4.1	State-of-the-Art PAT	321
9.4.2	QbD-based PAT Control Strategy	322
9.4.3	Process Simulation Toward APC-Based Autonomous Operation	323
9.4.4	Applicability of Spectroscopic Methods in Continuous Biomanufacturing	328
9.4.5	Proposed Control Strategy Including PAT	332
9.4.6	Evaluation and Summary of PAT	337
9.5	Conclusion	338
	Acknowledgments	339
	References	339

10 Regulatory and Quality Considerations of Continuous Bioprocessing 351

Britta Manser and Martin Glenz

10.1	Introduction	351
10.2	Integrated Processing	352
10.3	Process Traceability	353
10.3.1	Batch and Lot Definition	353
10.3.2	Lot Traceability and Deviation Management	354
10.4	Process Consistency	355
10.4.1	Process Control	356
10.4.1.1	Automation	356
10.4.1.2	Process Analytical Technologies (PAT)	357
10.4.1.3	Data Analysis	359
10.4.1.4	Real-Time Release Testing	360
10.4.2	Quality by Design	360
10.4.2.1	Multicolumn Protein A Chromatography	361
10.4.2.2	Continuous Virus Inactivation	362
10.4.2.3	Bind/Elute Cation Exchange Chromatography	362
10.4.2.4	Flow-Through Anion Exchange Chromatography	363
10.4.2.5	Ultrafiltration and Diafiltration	363
10.4.2.6	Sterile Filtration	363
10.4.2.7	Virus Reduction Filtration	363

10.4.2.8	Connection of Unit Operations	364
10.5	Patient Safety	365
10.5.1	Contamination Control	365
10.5.2	Virus Safety	366
10.5.2.1	Virus Reduction in Chromatography	367
10.5.2.2	Low-pH Virus Inactivation	367
10.5.2.3	Virus Reduction Filtration	368
10.6	Equipment Design	369
10.7	Conclusion	370
	References	371
	Index	377